Sepideh Hajian
1 
, Azadeh Zahedi Far
2* 1 Department of Nephrology, Velayat Clinical Research Development Unit, Qazvin University of Medical Sciences, Qazvin, Iran
2 Assistant Professor of Internal Medicine, Department of Internal Medicine, School of Medicine Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
Abstract
Chronic kidney disease (CKD) has historically been managed with a traditional mindset focused solely on delaying dialysis initiation rather than restoring renal function. This entrenched paradigm is shifting due to emerging evidence suggesting that significant disease regression and clinical remission are achievable goals. Here, we examine the therapeutic landscape transforming CKD management from mere slowdown to potential reversal. We discuss on sodium glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon like peptide 1 receptor agonists alongside lifestyle modifications including dietary protein restriction and blood pressure optimization. Data indicates that early intervention targeting hemodynamic stress, systemic inflammation, and renal fibrosis can restore glomerular filtration rates (GFRs) and reduce albuminuria below nephrotic thresholds. Furthermore, clinical guidelines should evolve to prioritize remission criteria, emphasizing on aggressive early treatment windows before irreversible scarring occurs. This remission revolution necessitates a fundamental change in physician expectations and patient education, moving away from inevitable decline toward active restoration. Finally, redefining success in CKD care requires integrating these novel agents into standard practice to halt progression and actively reverse damage, offering renewed hope and improved long term outcomes for the future global CKD population while significantly reducing the economic burden associated with end stage renal disease therapy.
Implication for health policy/practice/research/medical education:
Chronic kidney disease (CKD) management has historically prioritized delaying progression rather than restoring function. This paradigm shift, termed the remission revolution, explores emerging strategies aimed at achieving structural reversal of kidney injury. Traditional therapies focusing on hemodynamic control are now complemented by regenerative medicine, anti-fibrotic agents, and precision nutrition targeting underlying metabolic dysfunctions. This review considers current evidence demonstrating that early intervention with sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and novel anti-inflammatory pathways can induce partial remission in specific chronic kidney disease etiologies.
Please cite this paper as: Hajian S, Zahedi Far A. Remission revolution; redefining CKD management from slowdown to reversal. J Nephropharmacol. 2026;15(x):e12855. DOI: 10.34172/npj.2026.12855.